BeStock  
Stocks › Biotechnology › ARQT

Arcutis Biotherapeutics ARQT

US equityMarket cap rank #2353Biotechnology
$26.36 −$0.81 (-2.98%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $26.40 +0.15%
Open$26.91
Prev close$27.17
Day range$26.29 – $27.47
Volume1.29M
Market cap$3.33B
P/E (TTM)119.8
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$143.92M+45.1% YoY
Operating profit$9.44M+10.7% YoY
Net profit$8.80M+18.8% YoY
Diluted EPS$0.06+0.0% YoY
Free cash flow$18.80M+1,171.9% YoY
Operating cash flow$18.90M

Revenue, last 8 quarters

$71.4MDec '24$65.8MMar '25$81.5MJun '25$99.2MSep '25$129.5MDec '25$105.4MMar '26$129.9MJun '26$143.9MSep '26

Net profit, last 8 quarters

$-10.8MDec '24$-25.1MMar '25$-15.9MJun '25$7.4MSep '25$17.4MDec '25$-11.3MMar '26$15.0MJun '26$8.8MSep '26

Diluted EPS by quarter

-0.09Dec '24-0.20Mar '25-0.13Jun '250.06Sep '250.13Dec '25-0.09Mar '260.11Jun '260.06Sep '26

Free cash flow by quarter

$-5.7MDec '24$-31.0MMar '25$-9.8MJun '25$-1.8MSep '25$26.2MDec '25$2.2MMar '26$12.5MJun '26$18.8MSep '26

Annual revenue

$0.0FY20$0.0FY21$3.7MFY22$59.6MFY23$196.5MFY24$376.1MFY25

Profitability & balance sheet

Gross margin91.2%
Operating margin6.9%
Net margin5.9%
Return on equity14.9%
Return on assets6.7%
Return on invested capital10.8%
Current ratio2.92
Liabilities / assets53.5%
Cash & investments$259.46M
Total debt$114.62M
Net cash (debt)$144.84M
Free cash flow / sales11.7%

Where the revenue comes from

Quarter 2026/Q3

By business line

  • ZORYVE foam$75.14M 52.2%
  • ZORYVE cream 0.3%$37.78M 26.2%
  • ZORYVE cream 0.15%$27.26M 18.9%
  • ZORYVE cream 0.05%$3.74M 2.6%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $143.92M $129.86M $105.40M $376.07M $129.50M
Total Operating Revenue $143.92M $129.86M $105.40M $376.07M $129.50M
Cost of Revenue $12.46M $10.94M $9.78M $36.70M $11.69M
Gross Profit $131.46M $118.92M $95.61M $339.38M $117.82M
Operating Expense $122.02M $102.49M $104.70M $351.60M $99.43M
Selling and Admin Expenses $99.60M $82.14M $74.08M $274.55M $78.98M
Research & Development $22.42M $20.36M $30.63M $77.05M $20.45M
Operating Profit $9.44M $16.43M -$9.09M -$12.23M $18.39M
Net Non-Operating Interest Income (Expense) -$363,000.00 -$1.13M -$2.09M -$3.19M -$835,000.00
Non-Operating Interest Income $2.60M $2.28M $2.28M $8.90M $2.17M
Non-Operating Interest Expense $2.96M $3.41M $4.37M $12.08M $3.00M
Other Income (Expense) -$77,000.00 -$157,000.00 -$20,000.00 $443,000.00 $313,000.00
Other Non-Operating Income (Expenses) -$77,000.00 -$157,000.00 -$20,000.00 $443,000.00 $313,000.00
Pretax Profit $9.00M $15.15M -$11.20M -$14.97M $17.87M
Tax $195,000.00 $136,000.00 $93,000.00 $1.17M $470,000.00
Net Profit $8.80M $15.01M -$11.30M -$16.14M $17.40M
Profit from Continuing Operations $8.80M $15.01M -$11.30M -$16.14M $17.40M
Net Income to Parent Company $8.80M $15.01M -$11.30M -$16.14M $17.40M
Net Income to Common Stockholders $8.80M $15.01M -$11.30M -$16.14M $17.40M
Basic EPS $0.06 $0.11 -$0.09 -$0.13 $0.14
Diluted EPS $0.06 $0.11 -$0.09 -$0.13 $0.13

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $524.43M $488.54M $460.00M $432.97M $432.97M
Total Current Assets $503.69M $467.67M $438.06M $411.23M $411.23M
Cash and Cash Equivalents & Short-Term Investments $259.46M $238.55M $224.00M $220.98M $220.98M
-Cash and Cash Equivalents $33.37M $34.12M $34.76M $42.91M $42.91M
-Short Term Investments $226.09M $204.43M $189.24M $178.08M $178.08M
Receivables $171.28M $155.16M $144.38M $146.23M $146.23M
-Accounts Receivable $171.28M $155.16M $144.38M $146.23M $146.23M
Prepaid Assets $14.35M $19.56M $18.66M $12.06M $12.06M
Inventory $45.67M $38.88M $37.39M $22.63M $22.63M
Restricted Cash $308,000.00 $308,000.00 $308,000.00 $308,000.00 $308,000.00
Other Current Assets $12.62M $15.21M $13.32M $9.02M $9.02M
Total Non-Current Assets $20.74M $20.87M $21.95M $21.74M $21.74M
Net PPE $4.94M $5.13M $5.40M $5.51M $5.51M
-Gross PPE $4.94M $5.13M $5.40M $8.76M $8.76M
Goodwill and Other Intangible Assets $13.13M $13.69M $14.25M $14.81M $14.81M
Other Non-Current Assets $2.67M $2.05M $2.30M $1.42M $1.42M
Total Liabilities $280.46M $267.96M $270.36M $243.49M $243.49M
Total Current Liabilities $172.36M $160.34M $163.20M $129.84M $129.84M
Payables $8.34M $6.60M $18.30M $12.53M $12.53M
-Accounts Payable $8.34M $6.60M $18.30M $12.53M $12.53M
Current Accrued Expenses $135.43M $131.28M $126.63M $95.78M $95.78M
Short-Term Debt and Capital Lease Obligation $6.95M $6.95M $7.95M $1.00M $1.00M
-Current Debt $6.95M $6.95M $7.95M $1.00M $1.00M
Total Non-Current Liabilities $108.10M $107.62M $107.15M $113.66M $113.66M
Long Term Debt and Capital Lease Obligation $107.67M $107.19M $106.72M $113.23M $113.23M
-Long Term Debt $102.45M $101.95M $101.47M $107.96M $107.96M
-Long Term Capital Lease Obligation $5.22M $5.24M $5.25M $5.27M $5.27M
Other Non-Current Liabilities $431,000.00 $431,000.00 $431,000.00 $431,000.00 $431,000.00
Total Equity $243.97M $220.58M $189.65M $189.48M $189.48M
Stockholders' Equity $243.97M $220.58M $189.65M $189.48M $189.48M
Capital Stock $12,000.00 $12,000.00 $12,000.00 $12,000.00 $12,000.00
-Common Stock $12,000.00 $12,000.00 $12,000.00 $12,000.00 $12,000.00
Additional Paid-In Capital $1.37B $1.36B $1.34B $1.33B $1.33B
Retained Earnings -$1.13B -$1.13B -$1.15B -$1.14B -$1.14B
Gains/Losses Not Affecting Retained Earnings -$1.17M -$656,000.00 -$514,000.00 -$44,000.00 -$44,000.00
-Accumulated Depreciation – – – -$3.25M -$3.25M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $18.90M $12.64M $2.24M -$5.63M $26.19M
Net cash flow from continuing operations $18.90M $12.64M $2.24M -$5.63M $26.19M
Net Income from Continuing Operations $8.80M $15.01M -$11.30M -$16.14M $17.40M
Depreciation & Depletion & Amortization $562,000.00 $563,000.00 $562,000.00 $4.67M $563,000.00
Other Non-Cash Items $779,000.00 $757,000.00 $675,000.00 $2.41M $482,000.00
Change in Working Capital -$3.44M -$16.23M $1.79M -$34.83M -$2.33M
-Change in Receivables -$16.12M -$10.79M $1.85M -$73.16M -$31.11M
-Change in Inventory -$6.50M -$1.18M -$14.58M -$7.33M -$5,000.00
-Change in Prepaid Assets $7.18M -$2.55M -$11.73M -$2.01M -$1.27M
-Change in Payables and Accrued Expense $12.01M -$1.58M $26.38M $48.35M $30.18M
-Change in Other Current Liabilities -$8,000.00 -$139,000.00 -$137,000.00 -$680,000.00 -$126,000.00
Net cash flow from investing -$22.08M -$15.22M -$11.33M -$30.25M -$34.18M
Net Cash Flow from Continuing Investing Activities -$22.08M -$15.22M -$11.33M -$30.25M -$34.18M
Net PPE Purchase and Sale -$97,000.00 -$158,000.00 $0.00 -$686,000.00 $0.00
Net Intangibles Purchase and Sale $0.00 – – -$10.00M $0.00
Net Investment Purchase and Sale -$21.99M -$15.07M -$11.33M -$19.57M -$34.18M
Financing Cash Flow $2.45M $1.99M $1.07M $6.97M $3.72M
Net Cash Flow from Continuing Financing Activities $2.45M $1.99M $1.07M $6.97M $3.72M
Proceeds from Stock Option Exercised $2.45M $2.99M $1.07M $6.97M $3.72M
Net Other Financing Charges $0.00 – – – –
Ending Cash Balance $33.68M $34.43M $35.07M $43.22M $43.22M
Net Change in Cash -$733,000.00 -$595,000.00 -$8.03M -$28.91M -$4.27M
Beginning Cash Balance $34.43M $35.07M $43.22M $71.95M $47.43M
Effect of Exchange Rate Changes -$15,000.00 -$46,000.00 -$119,000.00 $168,000.00 $59,000.00
Free Cash Flow $18.80M $12.48M $2.24M -$16.31M $26.19M
Net Issuance Payments Of Debt – – – $0.00 –
Net Common Stock Issuance – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on ARQT.

Sign in to join the discussion.

Scroll to Top